Accepted starting material for INVIEW Liquid Biopsy Oncoprofiling (728 genes)
- 10 ml blood
- 4 ml plasma*
- 15 ng already isolated cell-free DNA (up to 30 µl / concentration > 0,5 ng/µl)
* If possible, please provide an additional aliquot. Prepare plasma according to provided protocol (See Files). Ship plasma on dry ice. Thawing of the plasma will lead to degradation of the cell-free DNA (cfDNA).
Additional Information
INVIEW Liquid Biopsy Oncoprofiling (728 genes) offers the most in-depth approach for tumour mutation profiling from plasma cell-free (cfDNA) via a targeted cancer gene panel. As a powerful non-invasive tool, this tumour panel enables monitoring of cancer specific mutations with high fidelity and sensitivity. The analysed material, ctDNA, is described as a specific and sensitive biomarker in multiple human cancers, which allows for comprehensive molecular profiling of the tumour. This cancer panel enables the detection of 728 clinically actionable genomic regions, including frequently mutated genes, such as BRAF, KRAS, EGFR, PIK3CA, HER2 and TP53. The scope of this mutation panel makes the product perfectly suitable for the investigation of nearly any type of cancer, including melanoma, bladder cancer, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, thyroid cancer, kidney cancer, liver cancer and lung cancer.
